Wednesday, November 4, 2026||
MultiKhabarMultiKhabar

NPPA exempts Biodeal’s indigenously developed midazolam nasal spray from price control for five years

Share:WhatsAppFacebookX (Twitter)Telegram
NPPA exempts Biodeal’s indigenously developed midazolam nasal spray from price control for five years
Photo / Coverage: The Hindu Business Line
EXECUTIVE SUMMARY

Midazolam 1.25 per cent w/v nasal spray is a prescription rescue medicine used primarily for the emergency treatment of acute repetitive seizures

Key Takeaways

  • NPPA exempts Biodeal’s indigenously developed midazolam nasal spray from price control for five years.

Midazolam 1.25 per cent w/v nasal spray is a prescription rescue medicine used primarily for the emergency treatment of acute repetitive seizures

Share:WhatsAppFacebookX (Twitter)Telegram

Read Complete Original Article

Published originally on The Hindu Business Line

Visit Publisher Site →

Related News

🇮🇳 India
Multikhabar App

All Information In One Place

Real-time headlines from trusted sources. Get the app now — stay updated, inspired, and ahead with breaking news!

Get it on Google Play